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Abstract
Introduction: The BET family of bromodomain-containing proteins constitute
epigenetic readers that bind to acetylated lysine residues of core histones, thereby
translating epigenetic histone marks to effects on gene expression. BET inhibitors
are currently emerging as promising therapeutic agents for treatment of various
pathological conditions. Here, we explored the potential of using BET inhibition to
modulate IgE-mediated responses in mast cells.
Methods:We assessed the effects of BET inhibitors PFI-1, I-BET151, and I-BET762
on responses downstream of mast cell activation through IgE receptor cross-
linking.
Results: BET inhibitors were neither toxic for mast cells (at doses up to 20mM),
nor did they prevent IgE-mediated mast cell degranulation. However, we found
that BET inhibition, in particular by I-BET151, suppressed IL-6 gene expression
and IL-6 protein release in response to IgE-mediated mast cell activation. This was
observed in both bone marrow-derived mast cells (BMMCs) and in mature
peritoneal-cell derived mast cells. Further analysis showed that BET inhibition also
suppressed the expression of a number of additional genes of those that were
upregulated by IgE receptor cross-linking, including IL-3, IL-7R, CCR1, and
ADAMTS9. However, BET inhibition was selective, i.e., several genes that were
upregulated by IgE receptor cross-linking were not affected by BET inhibitors.
Conclusions: These findings suggest that BET inhibition can interfere with the
upregulated expression of selected genes in mast cells activated by IgE receptor
cross-linking. Further, our findings introduce the concept of utilizing epigenetic
mechanisms for modulating mast cell function in the context of IgE-driven
disease.
Introduction
Mast cells are well known for their detrimental impact on
allergic disease, but are also important players in a range of
additional pathologies [1]. The classical mode of mast cell
activation, most notably in the context of allergic reactions,
is through binding of multivalent antigen to IgE molecules
bound to the high affinity IgE receptor, FceRI, on the mast
cell surface. The ensuing IgE receptor cross-linking will lead
to extensive release of preformed mediators from granular
stores, that is degranulation, but IgE-mediated activation
also results in the synthesis of numerous lipid-derived pro-
inflammatory mediators and expression of a panel of genes
coding for pro-inflammatory compounds [2, 3]. These latter
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include genes coding for cytokines, chemokines, and various
growth factors [3]. Altogether, mast cell activation through
IgE receptor cross-linking will thus lead to the release of a
wide array of pro-inflammatory compounds, which collec-
tively gives rise to a powerful inflammatory reaction.
Based on the powerful impact of mast cells on allergic and
other pathological conditions, there is a great demand for
therapeutic strategies that can counteract harmful mast cell
activities. Such strategies include the use of various mast cell
stabilizers and anti-IgE therapy to prevent mast
cell degranulation, as well as antagonists to the individual
mediators that are released following mast cell degranula-
tion [4]. However, there is also need for strategies that can
interfere with gene expression patterns that are induced
upon IgE-mediated mast cell activation.
Histone modification by various mechanisms, including
lysine acetylation, methylation, phosphorylation, and sumoyla-
tion is now established as a major epigenetic mechanism with
wide consequences for gene expression [5, 6]. The Bromodo-
main and extraterminal domain (BET) family of bromodomain
proteins bind specifically to acetylated lysine residues in core
histones, thereby transmitting the signal imposed by histone
acetylation into effects on gene expression [7]. Based on this
principle, inhibitors of BET proteins have been developed to
provide a novel means of directly modulating effects on gene
expression. Such inhibitors have subsequently been evaluated in
diverse settings and are currently regarded as promising
therapeutic agents in various pathological conditions, including
cancer, sepsis, and autoimmunity [8–12]. However, the
possibility of using BET inhibitors for modulating mast cell-
mediated events has hitherto not been explored.
Here, we investigated the effect of BET inhibition on mast
cell function. Our findings identify BET inhibition as a novel
means of modulating the expression of selected genes in
response to IgE-mediated mast cell activation. Hence, the
use of BET inhibitors could represent a new strategy to
directly interfere with gene expression patterns in patholog-
ical settings where mast cells are involved.
Methods
Reagents
Penicillin-streptomycin, L-glutamine, DMEM plus Gluta-
MAX, and minimum essential medium (MEM) non-
essential amino acids were from Invitrogen (Stockholm,
Sweden), whereas Dulbecco Modified Essential Medium
(DMEM), all salts for buffers, and the anti-DNP IgE
antibody were from Sigma (Stockholm, Sweden). DNP-HSA
was from Biosearch Technologies (Petaluma, CA). BET
protein inhibitors PFI-1 (PF-6405761), I-BET151
(GSK1210151A), and I-BET762 (GSK525762) were from
Sigma.
Cell culture
Bone marrow-derived mast cells (BMMCs) were obtained by
culturing bonemarrow cells from the femur and tibia of C57BL/6
mice as previously described [13]. The animal experiments were
approved by the local ethical committee (Uppsala djurf€ors€okse-
tiska n€amnd; approval no C 31/14). Peritoneal cell-derived mast
cells (PCMCs) [14] were obtained by maturation of cells from
peritoneal lavage of C57BL/6 mice as described [13].
Mast cell activation
Mast cells (BMMCs or PCMCs, at 1 106 cells/ml) were
sensitized overnight with IgE anti-DNP at 0.1mg/ml. The
next day, cells were washed twice and suspended in fresh
media or Tyrode’s buffer (130mMNaCl, 5mMKCl, 1.4mM
CaCl2, 1mM MgCl2, 5.6mM glucose, 10mM HEPES, and
0.1% BSA, pH 7.4) and stimulated for 1–24 h with DNP-
HSA (0.5mg/ml). In samples where BET inhibitors were
evaluated, mast cells were incubated for 1 h with BET
inhibitor (PFI-1, I-BET151, or I-BET762) at various
concentrations, followed by activation with DNP-HSA.
For cytokine/chemokine release and Western blot analysis,
activation with DNP-HSAwas performed for 4 or 24 h, while
for mRNA expression, mast cells were activated for 1 h.
Cytotoxicity test
Mast cells (BMMCs or PCMCs, at 106 cells/ml) were
incubated with serial dilutions of BET inhibitors (ranging
from 10 nM to 20mM) for 1 h. Cell viability was measured
using the Cell Titer-Blue1 cell viability assay (Promega-
Invitrogen, Carlsbad, CA) according to the recommenda-
tions of the manufacturer.
Cytokine/chemokine release
Supernatants from activated mast cells were analyzed for
levels of IL-6 and TNFa using ELISA kits as detailed by the
manufacturer (eBiosciences, San Diego, CA).
Beta-hexosaminidase assay
Supernatants from activated mast cells were analyzed for
their content of b-hexosaminidase activity as described [15]
as a measure of mast cell degranulation.
Total RNA isolation, quantitative real time
RT-PCR, and gene array analysis
Total RNA isolation and quantitative real time RT-PCR
(qPCR) was performed as described [13]. Hypoxanthine
guanine phosphoribosyl transferase (Hprt) was used as
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housekeeping gene [13]. Primers for IL-3,15 and 7r, CSF1,
CCR1, and NLRP3 are described in Table 1. Primers for Nr4a3
[16], ADAMTS9 [13], IL-6 and13 [17], and Cpa3 [18] were
as described. Data were calculated as DDCt relative to HPRT,
where values of the IgE-sensitized sample were set as 1. In
samples, where no signal corresponding to the sensitized
controls (IgE only) were detected, values for the IgEþDNP
group were set as 1. Gene array analysis was performed using
Affymetrix GeneChip1 expression arrays (GeneChip1Mouse
Gene 1.0 ST Array), as described previously [19].
Statistical analysis
Data shown are means standard error of the mean (SEM).
Statistical analyses were performed by using GraphPad
Prism 7.0 (GraphPad Software) and paired Student’s t-test
for two-tailed distributions. Differences were considered
significant if the P-values were 0.05 or less.
Results
BET inhibitors are non-cytotoxic for mast cells
To evaluate the impact of BET inhibition on mast cell
functionality, we first assessed whether BET inhibitors are
cytotoxic tomast cells (BMMCs). At doses up to 20mM,neither
of three testedBET inhibitors (PFI-1, I-BET151, I-BET762)were
cytotoxic tomast cells after 1h of incubation (Fig. 1A), and only
limited cytotoxicity at concentrations above 50nM were seen
after 24hof incubation (not shown). For the continuationof the
study, BET inhibitors were used at concentrations and
incubation times thatwerenon-toxic tomast cells (250nM;1h).
BET inhibition does not affect IgE-mediated mast
cell degranulation
Next, we assessed whether BET inhibition can interfere with
mast cell degranulation in response to IgE receptor cross-
linking. To this end, mast cells were pre-loaded with anti-
DNP IgE overnight, followed by IgE cross-linking by
addition of DNP-HSA, either in the presence or absence
of BET inhibitors. As seen in Figure 1B, IgE receptor cross-
linking resulted in a robust degranulation as measured by
b-hexosaminidase release. However, neither of the BET
inhibitors used caused any detectable reduction of this
response. Hence, BET inhibition does not affect IgE-
mediated mast cell degranulation.
BET inhibition suppresses IL-6 expression and
release in response to IgE receptor cross-linking
Earlier reports have shown that BET inhibition can suppress
IL-6 expression in response to TLR4 ligation in macro-
phages [8, 20]. In order to evaluate if BET inhibitors can
Table 1. Primers used for qPCR.







Figure 1. Effect of BET inhibition on viability and degranulation in bone
marrow-derived mast cells (BMMCs). (A) BMMCs (106cells/ml) were
treated for 1 h with the indicated concentrations of PFI-1, I-BET151, or I-
BET762. Cytotoxicity was evaluated using the Cell Titer-Blue1 cell
viability assay. (B) BMMCs (106cells/ml) were incubated for 1 h with
250nM of PFI-1, I-BET151, or I-BET762. Next, degranulation upon IgE-
receptor cross-linking was measured after 1 h as release of b-
hexosaminidase. Data shown represent means SEM of three indepen-
dent experiments. Paired Student's t-test for two-tailed distributions.
P< 0.05.
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modulate gene expression in IgE-activated mast cells, we
therefore first focused on IL-6. As depicted in Figure 2A, IgE
receptor cross-linking caused a strong upregulation of IL-6
gene expression. Moreover, it was seen that BET inhibition
resulted in a profound reduction of this response. In
particular, I-BET151 proved to be a highly potent inhibitor
of IL-6 expression. In contrast, although TNFa gene
expression was profoundly upregulated in response to IgE
receptor cross-linking in mast cells, neither of the BET
inhibitors was capable of suppressing the TNFa induction
(Fig. 2B). In agreement with these data, ELISA measure-
ments showed that BET inhibition also suppressed the
release of IL-6 protein in response to IgE receptor cross-
linking (Fig. 2C and D), whereas no effect on the release of
TNFa was seen (Fig. 2E and F).
BET inhibition modulates IL-6 expression in
peritoneal cell-derived mast cells
Although BMMCs are commonly used for studies ofmast cell
function, they are less mature than those mast cells that are
found in vivo. To test the impact of BET inhibition on fully
mature mast cells, we therefore developed PCMCs [14].
Importantly, PCMCs have previously been shown to
represent fully differentiated mast cells of connective tissue
subtype [14]. As for BMMCs, neither of the BET inhibitors at
Figure 2. BET inhibitors suppress IL-6 upregulation and release in activated bone marrow-derived mast cells (BMMCs). BMMCs (106cells/ml) were
incubated for 1 h with 250nM of PFI-1, I-BET151, or I-BET762. Next, cells were activated by IgE receptor cross-linking. After 1 h, cells were recovered for
qPCR analysis of the expression of IL-6 (A) and TNFa (B) mRNA. Culture supernatants were collected after 4 or 24 h as indicated, and the content of IL-6
(C, D) and TNFa (E, F) in the supernatants was measured using ELISA. Data shown represent means SEM of three independent experiments. Paired
Student's t-test for two-tailed distributions. P< 0.05; P< 0.01; P< 0.001; P< 0.0001.
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any of the tested concentrations showed cytotoxicity for
PCMCs, when incubated for 1 h with the cells (Fig. 3A). Also
after prolonged incubation (24 h), undetectable or only
marginal cytotoxicity was seen at concentrations above
100 nM (data not shown). In agreement with the effects
seen on BMMCs, BET inhibition did not affect the
degranulation of PCMCs in response to IgE receptor cross-
linking (Fig. 3B). In further accordance with the effects on
BMMCs, BET inhibition suppressed the expression of IL-6
mRNA in response to IgE receptor cross-linking and inhibited
the release of IL-6 protein in PCMCs (Fig. 3C and D). It was
also seen that BET inhibition down-regulated the baseline
Figure 3. Effect of BET inhibition on peritoneal cell-derived mast cells (PCMCs). (A) PCMCs (105cells/ml) were treated for 1 h with indicated
concentrations of PFI-1, I-BET151, or I-BET762 and cytotoxicity was evaluated using the Cell Titer-Blue1 cell viability assay. (B) PCMCs (106cells/ml) were
incubated for 1 h with 250 nM of PFI-1, I-BET151, or I-BET762. One hour after IgE receptor cross-linking, the extent of degranulation was measured as
release of b-hexosaminidase. (C and D) PCMCs (106cells/ml) were incubated for 1 h with 250 nM of PFI-1, I-BET151, or I-BET762. Cells were then
subjected to IgE receptor cross-linking, followed by assessment of IL-6 mRNA expression by qPCR (C; 1 h after activation) or measurement of IL-6 release
using ELISA (D; 24 h after activation). (E) PCMCs (106 cells/ml) were incubated for 1 h with different concentrations of I-BET151 followed by IgE receptor
cross-linking and quantification of IL-6 mRNA expression using qPCR. Data shown represent means SEM of three independent experiments. Paired
Student's t-test for two-tailed distributions. P< 0.05; P< 0.01; P< 0.001; P< 0.0001.
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Figure 4. BET inhibition prevents upregulation of IL-3, IL-7r, CCR1, and NLRP3 in activated peritoneal cell-derived mast cells (PCMCs). PCMCs (106 cells/
ml) were treated for 1 hwith 250 nMof BET inhibitor andwere then activated for 1 h by IgE-receptor cross-linking.mRNA levels corresponding to IL-3 (A),
IL-13 (B), IL-15 (C), IL-7r (D), CSF1 (E), CCR1 (F), Nr4a3 (G), ADAMTS9 (H), CPA3 (I), and NLRP3 (J) were evaluated using qPCR. Data shown are
means SEM of three independent experiments. Paired Student's t-test for two-tailed distributions. P< 0.05; P< 0.01; P< 0.001.
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Figure 5. BET inhibition regulates gene expression in bonemarrow-derivedmast cells (BMMCs). BMMCs (106 cells/ml) were treated for 1 hwith 250 nM
of BET inhibitor andwere then activated for 1 h by IgE-receptor cross-linking.mRNA levels corresponding to IL-3 (A), IL-13 (B), IL-15 (C), IL-7r (D), CSF1 (E),
CCR1 (F), Nr4a3 (G), ADAMTS9 (H), CPA3 (I), and NLRP3 (J) were evaluated using qPCR. Data shown represent means SEM of three independent
experiments. Paired Student's t-test for two-tailed distributions. P< 0.05; P< 0.01.
G. Garcia-Faroldi et al. Mast cells and BET inhibition
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expression of IL-6. As for BMMCs, BET inhibitor I-BET151
wasmore effective than PFI-1 and I-BET762. A dose response
experiment showed that optimal inhibition of IL-6 gene
expression was obtained at 250nM of I-BET151 (Fig. 3E).
BET inhibition represses the expression of
selected genes that are upregulated by IgE
receptor cross-linking
To provide a deeper insight into whether BET inhibition
affects gene expression in IgE-activatedmast cells beyond the
effects on IL-6 (see Figs. 1 and 2), we performed a gene array
analysis to search for additional genes affected by BET
inhibitors. To this end, we performed a gene array analysis of
PCMCs activated by IgE receptor cross-linking, either in the
absence or presence of BET inhibitor I-BET151. As expected,
this analysis suggested that a large number of protein-
encoding genes were upregulated in response to IgE receptor
cross-linking (Suppl. Table S1). Further, the gene array data
indicated that only selected genes were substantially affected
by BET inhibition (Suppl. Table S2). These included IL-6,
NLRP3, IL-7R, IL-3, CCR1, ADAMTS9, IL-15, and IL-13. To
confirm the findings obtained through the gene array screen,
we used quantitative real time PCR (qPCR). As shown in
Figure 4, the qPCR analysis indeed revealed a robust
induction of the IL-3 (Fig. 4A), IL-13 (Fig. 4B), IL-7R
Fig. 4D), CSF1 (Fig. 4E), CCR1 (Fig. 4F), and ADAMTS9
(Fig. 4H) genes in PCMCs subjected to IgE receptor cross-
linking. We also noted that Nr4a3, a gene that previously was
shown to be one of the most highly induced genes in mast
cells activated by various means [16], was strongly
upregulated in IgE-activated PCMCs (Fig. 4G). Out of these
genes, the expression of IL-3, IL7R (coding for the IL-7
receptor), and CCR1 (receptor for chemokines CCL3, 5,
7, and 23) was suppressed by BET inhibition. Also the
expression ofNLRP3 (a key inflammasome component [21])
was suppressed by BET inhibition, although the qPCR
analysis did not support upregulatedNLRP3 expression after
IgE receptor cross-linking (Fig. 4J). As for IL-6 (see Fig. 3),
BET inhibitor I-BET151 was more effective than the other
BET inhibitors. Notably, although the qPCR analysis
confirmed an upregulated expression of IL-13, CSF1, and
Nr4a3 after IgE receptor cross-linking, no effect of BET
inhibition was seen on the expression of any of these genes.
For ADAMTS9 (a metalloprotease), a trend of suppression
was seen but this did not reach statistical significance.
Further, BET inhibition did not affect the expression of the
IL-15 gene (Fig. 4B). We also tested the effect of BET
inhibition on Cpa3, a secretory granule-contained protease
that serves as a major mast cell marker [2]. Cpa3 expression
was not affected by IgE receptor cross-linking and,
moreover, there was no effect of BET inhibition on Cpa3
expression (Fig. 4I).
To extend these observations, we additionally evaluated
whether BET inhibition had an impact on the expression of
the corresponding genes in BMMCs, that is in less mature
mast cells. As seen in Fig. 5, IgE receptor cross-linking caused
upregulation of the genes coding for IL-3 (Fig. 5A), IL-13
(Fig. 5B), CSF1 (Fig. 5E), CCR1 (Fig. 5F), Nr4a3 (Fig. 5G),
ADAMTS9 (Fig. 5H), and NLRP3 (Fig. 5J) along with a
trend of upregulated expression of the Il-7R gene (Fig. 5D),
that is similar findings as for PCMCs. However, BMMCs
were generally less responsive to BET inhibition in
comparison with PCMCs, with only the expression of the
ADAMTS9 (Fig. 5H) and IL-15 (Fig. 5C) genes being
significantly repressed by any of the BET inhibitors.
However, trends of inhibition were seen for the IL-7R
(Fig. 5D) and CCR1 (Fig. 5F) genes. As in PCMCs, Cpa3
expressionwas neither affected by IgE receptor cross-linking,
nor by BET inhibition (Fig. 5I).
Discussion
BET inhibitors have previously been assessed in a variety of
settings and are currently emerging as promising therapeutic
agents (see Introduction). However, the possibility of using
this type of inhibitors to intervene with mast cell functions
has, to our knowledge, not been addressed before. Here, we
show that gene expression in mast cells activated by IgE
receptor cross-linking can be modulated by inhibition of the
BET proteins. One important implication of these findings is
that responses downstream of IgE-mediated mast cell
activation can be influenced by epigenetic mechanisms. In
line with our findings, it was recently shown that interference
with BRD4, one of the BET family members can suppress
growth and induce apoptosis in neoplastic mast cells [22].
Hence, modulation of BET proteins could potentially
represent a novel means of modulating mast cell-mediated
events in a variety of settings.
It is apparent from the present study that BET inhibitors
do not interfere with mast cell degranulation. It is therefore
unlikely that BET inhibition has effects on the immediate
response downstream of mast cell activation, that is events
related to effects of the preformed mast cell mediators
released from secretory granules. Instead, BET inhibition
was shown to modulate gene expression patterns in
response to IgE receptor cross-linking, thus implicating
BET inhibitors as possible agents to modulate events
occurring in the late phase responses following mast cell
activation. However, it was noted that BET inhibition also
suppressed the baseline expression of several of the
assessed genes. Hence, BET-mediated regulation of gene
expression in mast cells is not restricted to situations in
which they are activated.
One of the main findings was that BET inhibition
potently suppressed the upregulation of IL-6, both at the
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gene and protein level. This is thus in analogy with
previous studies demonstrating that BET inhibitors can
suppress IL-6 expression in macrophages stimulated
with TLR4 ligands [8, 20]. Based on the findings
presented here, we may propose that BET inhibition
can be used as a therapeutic strategy to modulate IL-6
gene expression in mast cells. Importantly, mast cell-
derived IL-6 has been implicated in a variety of
pathological contexts, including atherosclerosis [23],
stroke pathology [24], arthritis [25], Th17 skewing [26],
mastocytosis [27], and diabetes [28]. Hence, modulation
of IL-6 expression by BET inhibition could have a
therapeutic potential in such settings.
Besides the IL-6 gene, we here identified a number of
additional genes whose expression in IgE-activatedmast cells
was affected by BET inhibition. These included IL-3, IL-7R,
and CCR1, all of which have established and important
functions in inflammatory responses. Of note, IL-3 is a
potent growth factor for mast cells [29], and the suppression
of IL-3 expression by BET inhibition might thus interfere
with IL-3-driven mast cell proliferation. Potentially, reduc-
tion of mast cell numbers by inhibition of BET proteins
could thus have beneficial effects under circumstances when
mast cells account for aggravating activities, for example in
allergic asthma and mastocytosis. We also found that BET
inhibition suppressed the expression of NLRP3. It is thus
possible that BET inhibition could represent a novel strategy
for interfering with inflammasome activity. In addition, the
expression of ADAMTS9, a protease that recently was
identified as a mast cell signature gene [30] and to be highly
upregulated by IgE receptor cross-linking [13], was sup-
pressed in mast cells subjected to BET inhibition. As
ADAMTS9 is implicated in connective tissue remodeling
events [31], BET inhibition could thus counteract such
processes orchestrated by mast cells.
In summary, this study identifies BET inhibitors as novel
agents with capacity to modulate mast cell gene expression.
Importantly, the use of BET inhibition to modulate gene
expression in mast cells constitutes a novel principle for
intervening with mast cell function, in which gene
expression is directly targeted rather than being modulated
by targeting of signaling molecules that act upstream of the
gene transcription apparatus.
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